Who founded Amphix Bio?

Amphix Bio was founded by Samuel Stupp, Nicholas Sather, Nick Sather, Dévora Grynspan.

How much funding has Amphix Bio raised?

Amphix Bio has disclosed $10.3M raised across 1 round.

Where is Amphix Bio headquartered?

Amphix Bio is headquartered in Chicago, US.

Amphix Bio

Chicago, US · Delaware corporation

Amphix Bio develops peptide therapeutics based on a supramolecular chemistry platform that forms nanostructure scaffolds to activate regenerative signaling in cells and tissues. Its pipeline targets neurological injuries, neuro-inflammatory diseases, and musculoskeletal disorders.

BiotechDeep Tech

Founders & leadership

Samuel StuppCo-founder & Chief Scientific Officer

Nicholas SatherCo-founder

Nick SatherCo-founder & Chief Executive Officer

Dévora GrynspanCo-founder, Board Observer & Secretary

Board

Kok-Wai WongBoard director

Stephen R WilsonBoard director

John PotocsnakBoard director

Competitors · 2

by search overlap

Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Phigenix16 shared keywordsPhigenix develops personalized medicine for cancer, including companion diagnostics and targeted therapies for prostate and breast cancer patients. Its work centers on early detection and targeted inhibition of PAX2 and EN2 oncogenes and a cancer vaccine using Human Beta Defensin-1 (DEFB1) mRNA to direct the immune system against cancer cells.

Companies competing with Amphix Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements

$10.3M disclosed across 1 round · 2025

▶$10.3MraisedDec 2025 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Samuel StuppExecutive Officer, Director
Kok-Wai WongDirector
Stephen R WilsonDirector
John PotocsnakDirector
Nicholas SatherExecutive Officer, Director

Offering amount: $12.5M
Amount sold: $10.3M
First sale: Dec 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Science Foundation	Phase I	2022	$252.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Amphix Bio do?: Amphix Bio develops peptide therapeutics based on a supramolecular chemistry platform that forms nanostructure scaffolds to activate regenerative signaling in cells and tissues. Its pipeline targets neurological injuries, neuro-inflammatory diseases, and musculoskeletal disorders.
Who founded Amphix Bio?: Amphix Bio was founded by Samuel Stupp, Nicholas Sather, Nick Sather, Dévora Grynspan.
How much funding has Amphix Bio raised?: Amphix Bio has disclosed $10.3M raised across 1 round.
Where is Amphix Bio headquartered?: Amphix Bio is headquartered in Chicago, US.